| Literature DB >> 29790485 |
Kaining Lu1,2, Shan Yu3, Meng Yu4, Dan Sun1,2, Zhihong Huang1,2, Haotian Xing1,2, Jianbin Bi1, Zeliang Li1, Zhenhua Li1, Xiankui Liu1, Chuize Kong1,2, Yuyan Zhu1,2.
Abstract
BACKGROUND Cancer immunotherapy is the use of the immune system to treat cancer. After years of research, there have been a significant number of publications in this field. We analyzed the literature and performed a hotspot analysis to identify important areas of future scientific research. MATERIAL AND METHODS Articles (2945) related to cancer immunotherapy published in the past 3 years were selected as the research sample. BICOMB software was then used to retrieve the high-frequency words and construct a text/co-word matrix. Next, gCLUTO software was used to analyze the matrix by double-clustering and visual analysis, in a strategy of hotspot identification. RESULTS We constructed a text and co-word matrix composed of 40 high-frequency words and 2945 articles and generated a hotspot "peak map" based on double-clustering analysis. The strategic coordinates were set by use of a co-word matrix and clustering analysis. The distribution of organs or disease and the subclass of cancer immunotherapy were analyzed. CONCLUSIONS In this study, we classified the hot-spots of "tumor immunotherapy" into 6 categories and 8 aspects. Calculation and analysis revealed that the field of tumor immunotherapy shows a slight trend of polarization, and the immune checkpoint inhibitor PD1 blocker shows the greatest potential for future development.Entities:
Mesh:
Year: 2018 PMID: 29790485 PMCID: PMC5994141 DOI: 10.12659/MSM.910724
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
High-frequency major MeSH terms from the included publications on tumor immunotherapy (n=2950).
| No. | MeSH terms | Frequency n (%) | Cumulative percentage, % |
|---|---|---|---|
| 1 | Immunotherapy/methods | 1134 (8.12) | 8.1296 |
| 2 | Neoplasms/therapy | 666 (4.77) | 12.9042 |
| 3 | Immunotherapy | 618 (4.43) | 17.3346 |
| 4 | Neoplasms/immunology | 308 (2.20) | 19.5426 |
| 5 | Immunotherapy, adoptive/methods | 265 (1.89) | 21.4424 |
| 6 | Antineoplastic agents/therapeutic use | 228 (1.63) | 23.0769 |
| 7 | Antibodies, monoclonal/therapeutic use | 224 (1.60) | 24.6828 |
| 8 | T-Lymphocytes/immunology | 204 (1.46) | 26.1452 |
| 9 | Melanoma/therapy | 152 (1.08) | 27.2349 |
| 10 | Cancer vaccines/therapeutic use | 116 (0.83) | 28.0665 |
| 11 | Cancer vaccines/immunology | 111 (0.79) | 28.8623 |
| 12 | Immunotherapy, adoptive | 105 (0.75) | 29.6150 |
| 13 | Neoplasms/drug therapy | 96 (0.68) | 30.3032 |
| 14 | Antigens, neoplasm/immunology | 96 (0.68) | 30.9915 |
| 15 | Lung neoplasms/therapy | 94 (0.67) | 31.6654 |
| 16 | Immunotherapy/trends | 92 (0.65) | 32.3249 |
| 17 | Uterine cervical neoplasms/prevention & control | 87 (0.62) | 32.9486 |
| 18 | Dendritic cells/immunology | 87 (0.62) | 33.5723 |
| 19 | Papillomavirus infections/prevention & control | 85 (0.60) | 34.1817 |
| 20 | Brain neoplasms/therapy | 84 (0.60) | 34.7839 |
| 21 | Antineoplastic combined chemotherapy protocols/therapeutic use | 80 (0.57) | 35.3574 |
| 22 | Receptors, antigen, T-Cell/immunology | 79 (0.56) | 35.9237 |
| 23 | T-Lymphocytes/transplantation | 73 (0.52) | 36.4471 |
| 24 | Molecular targeted therapy/methods | 70 (0.50) | 36.9489 |
| 25 | Killer cells, natural/immunology | 67 (0.48) | 37.4292 |
| 26 | Immunotherapy/adverse effects | 60 (0.43) | 37.8593 |
| 27 | Melanoma/drug therapy | 60 (0.43) | 38.2895 |
| 28 | Skin neoplasms/therapy | 59 (0.42) | 38.7125 |
| 29 | T-lymphocytes, cytotoxic/immunology | 58 (0.41) | 39.1283 |
| 30 | Glioblastoma/therapy | 57 (0.40) | 39.5369 |
| 31 | Programmed cell death 1 receptor/antagonists & inhibitors | 54 (0.38) | 39.9240 |
| 32 | Carcinoma, non-small-cell lung/therapy | 52 (0.37) | 40.2968 |
| 33 | Melanoma/immunology | 52 (0.37) | 40.6696 |
| 34 | Vaccination | 52 (0.37) | 41.0424 |
| 35 | Radioimmunotherapy/methods | 52 (0.37) | 41.4152 |
| 36 | CD8-positive T-lymphocytes/immunology | 51 (0.36) | 41.7808 |
| 37 | Molecular targeted therapy | 50 (0.35) | 42.1392 |
| 38 | Liver neoplasms/therapy | 44 (0.31) | 42.4547 |
| 39 | Antineoplastic agents/administration & dosage | 44 (0.31) | 42.7701 |
| 40 | Carcinoma, hepatocellular/therapy | 39 (0.27) | 43.0497 |
High-frequency major MeSH terms-source articles matrix (localized).
| No. | Major MeSH terms | PubMed Unique Identifiers of source article | ||||
|---|---|---|---|---|---|---|
| 24051308 | 24141774 | 24240689 | … | 25440606 | ||
| 1 | Immunotherapy/methods | 0 | 0 | 1 | … | 0 |
| 2 | Neoplasms/therapy | 1 | 1 | 0 | … | 0 |
| 3 | Immunotherapy | 1 | 1 | 0 | … | 0 |
| 4 | Neoplasms/immunology | 0 | 0 | 0 | … | 0 |
| ... | … | … | … | … | … | … |
| 39 | Antineoplastic agents/administration & dosage | 0 | 0 | 0 | … | 0 |
| 40 | Carcinoma, hepatocellular/therapy | 0 | 0 | 0 | … | 0 |
Descriptive and discriminating features and representative articles.
| Descriptive and Descriminating features | ||||
|---|---|---|---|---|
| Descriptive | 26826045 | 25300588 | 26845632 | 27488178 |
| Descriminating | 26868944 | 27488178 | 26826045 | 26291437 |
| Descriptive | 27188748 | 26059190 | 24691976 | 25929570 |
| Descriminating | 27188748 | 24691976 | 26059190 | 27410037 |
| Descriptive | 26998495 | 26384559 | 28347250 | 26332003 |
| Descriminating | 26384559 | 26998495 | 26332003 | 28347250 |
| Descriptive | 27259558 | 27302423 | 25640488 | 26837440 |
| Descriminating | 27259558 | 27123564 | 27769635 | 26181188 |
| Descriptive | 27706668 | 25196947 | 25904595 | 26923002 |
| Descriminating | 27706668 | 25196947 | 25904595 | 26923002 |
| Descriptive | 28387388 | 27710977 | 26578726 | 27438833 |
| Descriminating | 28387388 | 27710977 | 26578726 | 26250412 |
Figure 1Visualized matrix of biclustering of highly frequent major MeSH terms and PubMed Unique Identifiers (PMIDs) of articles on cancer immunotherapy.
Figure 2Mountain visualization of biclustering of highly frequent major MeSH terms and articles on tumor immunotherapy.
A co-word matrix of high-frequency major MeSH terms (localized).
| No. | Mesh terms | Immunotherapy/methods | Neoplasms/therapy | ... | Carcinoma, hepatocellular |
|---|---|---|---|---|---|
| 1 | Immunotherapy/methods | 1134 | 308 | ... | 18 |
| 2 | Neoplasms/therapy | 308 | 666 | ... | 0 |
| ... | ... | ... | ... | ... | ... |
| 40 | Carcinoma, hepatocellular | 18 | 0 | ... | 39 |
The centrality and density of the 6 clusters.
| Cluster | Intra-class link averages | Density-Y | Inter-class link average | Centralit-X |
|---|---|---|---|---|
| 0 | 34 | −4.66 | 1.68 | −3.01 |
| 1 | 22.25 | −16.41 | 2.52 | −2.17 |
| 2 | 44.03 | 5.37 | 4.92 | 0.228 |
| 3 | 22.7 | −15.96 | 3.57 | −1.12 |
| 4 | 68.5 | 29.91 | 8.55 | 3.86 |
| 5 | 40.42 | 1.76 | 6.9 | 2.21 |
| Average | 38.65 | 4.69 |
Figure 3A survey of major topics in tumor immunotherapy and cancer immunotherapy is shown. The visualizations were done using the Carrot system based on the top-ranking results of search. (A) Search results of tumor immunotherapy. (B) Search results of cancer immunotherapy.
Figure 4Strategic diagram of clusters.
Literature count of affected organ or disease.
| Organ/disease & literature count | ||
|---|---|---|
| Brain tumor (19/594) | Lung cancer (59/594) | Cervix cancer(27/594) |
| Glioma (31/594) | Liver cancer (25/594) | Skin cancer (5/594) |
| Cancer of head & neck (7/594) | Thyroid gland (1/594) | Myeloma (9/594) |
| Pancreatic cancer (20/594) | Bladder cancer (20/594) | Lymphoma (35/594) |
| Colon & rectum (34/594) | Prostate cancer (12/594) | Leukaemia (50/594) |
| Stomch (8/594) | Renal carcinoma (21/594) | Other blood disease(27/594) |
| Mallanoma (88/594) | Endometrium (1/594) | Oronasa cancer (6/594) |
| Cholangio carcinoma (3/594) | Ovary cancer(11/594) | Oral tumor (2/594) |
| Sarcoma (14/594) | Breast cancer(27/594) | Rare tumor (32/594) |
Figure 6Affected organ or disease distribution of tumor immunotherapy.
Figure 5Weight and distribution of each subcategory in tumor immunotherapy.